

Amendments in the Claims:

1. (Canceled)

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Canceled)

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Canceled)


15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Previously Presented) A compound having the formula:



wherein:

X is CH;

Y is oxygen;

Z is oxygen;

R is CO<sub>2</sub>H;

R<sup>2</sup> is methyl;

R<sup>3</sup> is methyl;

R<sup>4</sup> is phenyl;

R<sup>5</sup> is phenyl; and

R<sup>6</sup> is methyl,

or a pharmaceutically acceptable salt thereof.

20. (Previously Presented) The compound of claim 19, wherein said compound is an optically active enantiomer.


21. (Previously Presented) The compound of claim 20, wherein the enantiomer is the S enantiomer.

22. (Previously Presented) The compound of claim 21, wherein the enantiomer is the pure form of the S enantiomer.

23. (Previously Presented) The compound of claim 20, wherein the enantiomer is the R enantiomer.

24. (Previously Presented) The compound of claim 23, wherein the enantiomer is the pure form of the R enantiomer.

25. (Previously Presented) A pharmaceutical composition comprising a compound having the formula:



wherein:

X is CH;

Y is oxygen;

Z is oxygen;

R is CO<sub>2</sub>H;

R<sup>2</sup> is methyl;

R<sup>3</sup> is methyl;

R<sup>4</sup> is phenyl;

R<sup>5</sup> is phenyl;

R<sup>6</sup> is methyl; or a

pharmaceutically acceptable salt thereof,

and a pharmaceutically acceptable carrier.

26. (Previously Presented) The composition of claim 25, wherein said composition is suitable for oral, parenteral, or nasopharyngeal delivery.
27. (Previously Presented) The composition of claim 25, wherein the composition is in a solid form.
28. (Previously Presented) The composition of claim 25, wherein the composition is in a liquid form.
29. (Previously Presented) The composition of claim 25, wherein the composition is in the form of a tablet, capsule, powder, granule, suppository, solution, colloid, ointment, cream, vapor or spray.
30. (Previously Presented) The composition of claim 25, wherein the carrier comprises a tablet binder, filler, preservative, tablet disintegrant, flow regulator, plasticizer, wetting agent, dispersant, emulsifier, solvent, release-slowing agent, antioxidant, or propellant gas.
31. (Previously Presented) The composition of claim 25, wherein the compound is an optically active enantiomer.
32. (Previously Presented) The composition of claim 31, wherein the enantiomer is the S enantiomer.
33. (Previously Presented) The composition of claim 32, wherein the enantiomer is the pure form of the S enantiomer.
34. (Previously Presented) The composition of claim 31, wherein the enantiomer is the R enantiomer.
35. (Previously Presented) The composition of claim 34, wherein the enantiomer is the pure form of the R enantiomer.

36. (Cancel)

37. (Cancel)

38. (Cancel)

39. (Cancel)

40. (Cancel)

41. (Cancel)

42. (Cancel)

43. (Cancel)

44. (Cancel)

45. (Cancel)

46. (Cancel)

47. (Cancel)

48. (Cancel)

49. (Cancel)

50. (Cancel)

51. (Cancel)

52. (Cancel)

53. (New) The compound

